Stopping pimecrolimus cream did not lead to a rebound of skin symptoms in most of the patients who entered the follow-up phase, they also report.

As expected, pimecrolimus was well tolerated, the team reports, noting that there were no drug-related serious adverse effects.

Pimecrolimus was most effective in patients with corticosteroid-induced POD. Pimecrolimus-treated patients reported greater gains in quality of life than control-treated patients.